News

Asep Inc. Appoints General Wesley Clark (Ret.), David Johnson, J. Bernard Rice, Dr. Islam Mohamed and Thomas O’Shaughnessy to its Advisory Board and Dr. Rob Stenstrom, as Medical Director

Asep Inc. Signs Joint Venture Term Sheet with Leading Chinese Medical Diagnostic Company Sansure Biotech Inc. in Preparation for the Commercialization of the SepsetER Sepsis Diagnostic Test in China

Asep Medical Holdings Inc. Announces Adoption of Long-term Performance Incentive Plan, Grant of Stock Options

Asep Medical Holdings Inc. to Hold Important Investor Information Webinar on January 24, 2023

Asep Inc. Signs Letter of Intent for Joint Venture with Bahrain-based Seaspring W.L.L. for Regulatory Approval and Commercialization of Sepsis Diagnosis Technology in the Kingdom of Bahrain, the Middle East and North Africa

CLARIFICATION Asep Medical Holdings Inc. Provides Update on its Prior Disclosure Regarding Proprietary Diagnostic & Therapeutic Technologies

Asep Medical Holdings Inc. Achieves Significant Milestones Addressing Antibiotic Failure Through Proprietary Diagnostic & Therapeutic Technologies

Asep Inc. Completes Non-Brokered Private Placement of a $330,000 Unsecured Convertible Debenture

Asep Medical Holdings Inc. Enters into Commercial Agreement to Acquire SafeCoat Medical Inc.

Asep Medical Holdings Inc. Announces Grant of Stock Options

Asep Medical Holdings Inc. Announces Listing of its Common Shares on the Frankfurt Stock Exchange

Asep Inc. is Granted Patent Approval for its Sepsis Diagnostic Technology in 13 European Countries and Australia

Asep Inc. Signs Agreement with Bohai Biomedical Technology Development Co., Ltd., to Establish the Feasibility of Peptide-based Oral Rinse for the Chinese Market

Asep Inc. Announces the Appointment of Jacqueline M. Tucker as CFO

Dr. Richard Heinzl, Physician, Humanitarian, Entrepreneur and Author Appointed to Asep Inc.’s Board of Directors

Pandemic Preparedness — Asep Inc. supports World Sepsis Day (September 13th) and announces the development of a test kit to identify severe sepsis, the leading cause of death and morbidity in pandemics

Asep Medical Inc. Announces Appointment of Dr. Robert E. W. Hancock as CEO and Chairman

Asep Medical Holdings Inc. Receives Revocation of Cease Trade Order from the BC Securities Commission.

Asep Medical Holdings Inc. Taking Actions for Revocation of Cease Trade Order

Asep Medical Holdings Inc. Announces Additional Listing to the OTCQB Venture Market in the U.S.

Asep Medical Holdings Inc. Announces Compelling Results of an Independent Sepsis Study Prepared by RTI Health Solutions

Asep Medical Holdings Inc. to Hold Online Investor Information Webinar on March 3, 2022

Asep Medical Inc. Announces its Antibiofilm/Anti-inflammatory Peptide Technology is in Advanced Development for Wound Dressings with US Army Funding1

Asep Medical Holdings Inc. Announces an Exclusive Licensing Arrangement for a Patented and Novel AI-Driven Sepsis Diagnosis Technology Developed at the University of British Columbia (UBC)

ASEP Medical Holdings Inc. Announces Additions to its Advisory Board, IR Team, and Digital Marketing Programs

ASEP Medical Holdings Inc. Announces Public Listing on Case to Drive Fight Against Antibiotic Failure